Forward P/S Multiple: NeuroPace (NPCE)

NeuroPace, Inc. - graphic logo of issuer NPCE

NeuroPace, Inc. (NPCE) is implementing AI-powered neurostimulators for the autonomous correction of epileptic seizures. Production relies on robotic lines featuring optical quality control. The expected P/S valuation demonstrates the model's resilience, while 4.20 records a new level mark. The absence of competitors allows the company to exercise pricing power by setting premium rates for insurance organizations and clinics.

neuropace.com - NPCE Market Cap to Projected Revenue (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for NeuroPace Medical (NPCE)

- market price and analyst price targets:
Price Chart NeuroPace|NPCE - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization NeuroPace Medical|NPCE - Total Enterprise Value
- issuer book value statistics:
Book Value per Share NeuroPace|NPCE - Accounting Capitalization|Market Capitalization to Book Value Ratio neuropace.com|NPCE - Company Total Asset Base
- debt and liquidity data:
Total Debt to Capital NeuroPace, Inc.|NPCE - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital NeuroPace, Inc.|NPCE - Company Aggregate Debts|Debt to Book Capitalization Ratio NeuroPace Medical|NPCE - Company Long-Term Debt|Company Current Liabilities NeuroPace|Quick Ratio neuropace.com
- financial results and valuation multiples details:
NPCE - Company Net Income|Expected Profit NeuroPace, Inc.|NPCE - Market Cap to Net Income Ratio|Projected Price to Earnings NeuroPace Corp|NPCE - PEG Multiple|EV/EBITDA Multiple NeuroPace Medical|NPCE - Operating income before deduction of amortization|Earnings per share for the last twelve months NeuroPace|NPCE - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months neuropace.com|NPCE - Net earnings per share growth this year|Earnings growth forecast for next year NeuroPace, Inc.
- sales and revenue indicators:
NPCE - Company Total Revenue|Company Projected Revenue NeuroPace|NPCE - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple NeuroPace Medical
Fundamental company analysis:NPCE (NeuroPace)
Product sample of NeuroPace Medical

NeuroPace, Inc. (NPCE) specializes in the production of critical neurosurgical equipment, which renders the company's revenue resilient to macroeconomic shocks. By analyzing the projected P/S trend, an investor assesses the ratio of current market capitalization to expected sales, determining the extent to which the market is willing to pay a premium for future growth given the defensive nature of the business and long-term technology adoption cycles.

Who NeuroPace, Inc. competes with

Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward Price-to-Revenue Multiple Picard Group PMI|Forward P/S Multiple SRDX (Surmodics, Inc.)|Forward P/S Multiple senseonics.com SENS|TCMD - Price-to-Projected Revenue Ratio|SNWV: Price-to-Projected Revenue Ratio|OM (Outset) - Forward Price-to-Revenue Multiple|Electromed - Forward Price to Sales|LNSR (LENSAR, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio avitamedical.com RCEL|Price-to-Projected Revenue Ratio Profound Medical Corp. (PROF)|bairdmed.com (BDMD) - Projected Price to Revenue|EDAP TMS - Forward Price-to-Revenue Multiple|Forward P/S Multiple Apyx Medical Corp APYX|IceCure Medical, Ltd. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pulmonx Corporation LUNG|telabio.com (TELA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CTSO (CytoSorbents Corporation)|Price-to-Projected Revenue Ratio Sensus Healthcare Corp|Forward Price-to-Revenue Multiple Zynex Corp (ZYXI)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Inspira Technologies IINN|ICU: Market Cap to Projected Revenue|IRIX: Forward Price-to-Revenue Multiple|Intelligent Bio Solutions - Price to Expected Revenue Ratio|beyondair.net (XAIR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue PFSA|SSKN (STRATA Skin Sciences Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio glucotrack.com GCTK|Forward Price-to-Revenue Multiple NAOV (NanoVibronix)|Forward P/S Multiple Venus Concept Corporation (VERO)|Price-to-Projected Revenue Ratio Nuwellis, Inc. NUWE|Forward Price to Sales AEMD|ASXC - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Avinger Inc.|BioSig Technologies, Inc (BSGM) - Price-to-Projected Revenue Ratio|Future Price to Revenue CUTR (Cutera Inc)|KNW (Know Labs, Inc.) - Forward P/S Multiple|Forward P/S Multiple inarimedical.com|Forward P/S Multiple NVRO|Forward Price-to-Revenue Multiple reshapelifesciences.com RSLS|Forward P/S Multiple SILK (Silk Road Medical Inc.)